levofloxacin has been researched along with prothionamide in 6 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (prothionamide) | Trials (prothionamide) | Recent Studies (post-2010) (prothionamide) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 219 | 28 | 46 |
| Protein | Taxonomy | levofloxacin (IC50) | prothionamide (IC50) |
|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | 4.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS | 1 |
| Choi, JH; Heo, NY; Jo, KM; Kim, WG; Nam, KH; Park, CS; Park, SH | 1 |
| Adebola, SO; Adedeji, TO; Adefuye, BO; Oladeji, SM; Sogebi, OA | 1 |
| Bate, PNN; Chiwala, G; Fang, C; Guan, P; Hameed, HMA; Hu, J; Khan, SA; Liu, J; Liu, Z; Mugweru, JN; Tan, S; Tan, Y; Wang, B; Yusuf, B; Zhang, T; Zhong, N | 1 |
| Jiang, H; Li, X; Niu, Q; Xing, Z; Xu, J | 1 |
1 trial(s) available for levofloxacin and prothionamide
| Article | Year |
|---|---|
Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Area Under Curve; Cycloserine; Drug Monitoring; Fluoroquinolones; Healthy Volunteers; Humans; Kanamycin; Levofloxacin; Male; Moxifloxacin; Prothionamide; Pyrazinamide; Streptomycin; Young Adult | 2015 |
5 other study(ies) available for levofloxacin and prothionamide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Concomitant Drug Reaction with Eosinophilia and Systemic Symptom Syndrome from Ethambutol and Autoimmune Hepatitis from Isoniazid].
Topics: Alanine Transaminase; Antitubercular Agents; Cycloserine; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Eosinophilia; Ethambutol; Female; Hepatitis, Autoimmune; Humans; Isoniazid; Levofloxacin; Liver; Prothionamide; Severity of Illness Index; Tuberculosis; Young Adult | 2016 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; Coinfection; Comorbidity; Cycloserine; Diabetes Mellitus; Female; Hearing Loss; HIV Infections; Humans; Kanamycin; Levofloxacin; Male; Middle Aged; Nigeria; Prospective Studies; Prothionamide; Pyrazinamide; Risk Factors; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal; Drug Resistance, Bacterial; Levofloxacin; Mice, Inbred BALB C; Mice, SCID; Mycobacterium bovis; Mycobacterium tuberculosis; Plasmids; Prothionamide; Pyrazinamide; Tuberculosis, Pulmonary; Vaccines, Synthetic; Virulence | 2021 |
Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Topics: Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Levofloxacin; Linezolid; Mycobacterium tuberculosis; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Prothionamide; Pyrazinamide; Reactive Oxygen Species; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |